BioXcel Therapeutics (BTAI) Misses Q1 EPS by 22c

BioXcel Therapeutics (NASDAQ: BTAI) reported Q1 EPS of ($1.84), $0.22 worse than the analyst estimate of ($1.62). Revenue for the quarter came in at $210 thousand versus the consensus estimate of $447.1 thousand.

For earnings history and earnings-related data on BioXcel Therapeutics (BTAI) click here.

You May Also Be Interested In

• Academy Sports and Outdoor (ASO) Tops Q2 EPS by 22c, Offers Guidance
• Goldman Sachs hosts investor trip to Athens with Greek banks
• Core & Main, Inc (CNM) Tops Q3 EPS by 2c ; Offers Guidance